Requip (Ropinirole) IR 0.25–5 mg / ER 2–12 mg Tablets: Prescription Dopamine Agonist for Parkinson's Disease and Restless Legs Syndrome

Reviewed by the Lucas Clinic Medical Team | Updated May 2026

Ropinirole (Requip) is a non-ergot dopamine agonist with selective D2 and D3 receptor activity. It mimics the effect of dopamine by directly stimulating dopamine receptors in the striatum, bypassing the requirement for endogenous dopamine synthesis or conversion. Unlike levodopa, ropinirole does not require metabolic activation, which confers a smoother and more consistent receptor stimulation profile — this is mechanistically associated with lower rates of dyskinesia than levodopa in early Parkinson's disease, though direct comparisons must account for differences in disease severity at treatment initiation.

Ropinirole is FDA-approved for two distinct indications at very different dose ranges: Parkinson's disease (PD) and moderate-to-severe restless legs syndrome (RLS). The doses used for RLS are substantially lower than those for PD. Patients and caregivers must understand that these are separate dose ranges and that self-adjusting doses between indications is not appropriate. Both formulations — immediate-release (IR) Requip and extended-release (ER) Requip XL — are available. For RLS, only the IR formulation is used. Before prescribing ropinirole, thorough counselling about impulse control disorders (ICDs) is mandatory — this warning applies to all dopamine agonists as a class and is not unique to ropinirole.

What Is Requip (Ropinirole)?

Ropinirole's mechanism of action as a D2/D3 receptor agonist makes it particularly effective in the striatum — the brain region where dopaminergic signalling modulates motor control, reward processing, and other functions. The D3 receptor subtype (particularly prevalent in limbic regions) is implicated in the reward circuitry effects that are thought to contribute to impulse control disorders (ICDs) observed with dopamine agonists. This is not a rare or idiosyncratic reaction — studies report ICD rates of 14–17% in PD patients on dopamine agonists, with ropinirole and pramipexole the most commonly implicated agents. ICDs include pathological gambling, compulsive sexual behaviour (hypersexuality), binge eating, and compulsive shopping. The affected patient may lack awareness that their behaviour has changed; family and carer counselling is therefore as important as patient counselling.

For Parkinson's disease, ropinirole is used as initial monotherapy in early PD (particularly in younger patients to avoid or defer levodopa-related motor complications) or as adjunct therapy to levodopa/carbidopa in established PD to reduce motor fluctuations and extend the duration of levodopa benefit. For restless legs syndrome, a single dose of IR ropinirole is taken 1–3 hours before bedtime. Abrupt discontinuation of ropinirole in PD should never be attempted — rapid withdrawal can precipitate a neuroleptic malignant syndrome (NMS)-like reaction characterised by hyperthermia, rigidity, altered consciousness, and autonomic instability. Doses must always be tapered over weeks under medical supervision when stopping.

Prescription vs. Over-the-Counter Status

Ropinirole (Requip, Requip XL, and generics) is a prescription-only medication in all markets, reflecting the complexity and risk profile of dopamine agonist therapy. Prescribing and ongoing monitoring should be under neurological or specialist supervision, with regular assessment for impulse control disorders, excessive daytime sleepiness, and cardiovascular effects. The complexity of dosing titration schedules, particularly in PD, warrants specialist involvement in initiating and adjusting therapy.

Available Strengths and Forms

Requip (ropinirole IR): 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, and 5 mg immediate-release tablets. For Parkinson's disease: starting dose 0.25 mg TID (three times daily); titrated slowly upward (by 0.25 mg TID per week) to therapeutic response, typically in the range of 3–9 mg/day (up to 24 mg/day maximum in some PD patients). For restless legs syndrome: starting dose 0.25 mg daily (taken 1–3 hours before bed), titrated weekly up to a maximum of 4 mg/day for RLS.

Requip XL (ropinirole ER): 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg extended-release tablets taken once daily. Used for Parkinson's disease only (not RLS). Starting dose 2 mg once daily; titrated by 2 mg per day no more frequently than every 1–2 weeks; maximum dose 24 mg/day. Tablets must be swallowed whole — crushing, chewing, or splitting alters extended-release kinetics.

Price of Requip / Ropinirole

Branded Requip and Requip XL are largely superseded by generic ropinirole, which is widely available and substantially cheaper. Generic ropinirole IR (30 tablets of 0.25 mg or 1 mg) costs approximately $10–$30/month at US pharmacies with GoodRx discounts. Higher doses used in PD (e.g., 3 mg × 3/day) cost more — approximately $30–$80/month. Generic ropinirole ER tablets are similarly available at reduced cost relative to branded Requip XL. With Medicare Part D or commercial insurance covering generic ropinirole, out-of-pocket costs can be minimal. Without insurance, GoodRx and similar discount programmes offer meaningful savings. Branded Requip is rarely the most cost-effective choice for most patients.

Frequently Asked Questions

What are the impulse control disorder (ICD) risks with ropinirole?

All dopamine agonists — ropinirole, pramipexole, cabergoline, rotigotine — carry a class-level labelling warning for impulse control disorders. Published evidence suggests 14–17% of Parkinson's patients on dopamine agonists develop clinically significant ICDs: these include pathological gambling (making large, high-frequency bets disproportionate to financial means), compulsive sexual behaviour (hypersexuality), binge eating, and compulsive spending/shopping. Family members frequently detect these changes before the patient does. Prescribers should screen for ICD at every clinic visit using structured questioning. Management of ICD typically involves dose reduction or discontinuation of the dopamine agonist — patients must be warned that dose reduction itself can be destabilising in established PD. The ICD risk must be explicitly discussed with every patient and family before initiating ropinirole or any dopamine agonist.

Does ropinirole cause sudden sleep attacks?

Yes. Ropinirole (like other dopamine agonists) can cause excessive daytime somnolence (EDS) and sudden onset of sleep — episodes of falling asleep without warning, at any time of day, including while driving or operating machinery. These sleep attacks may occur without preceding sleepiness. Patients must be counselled before starting ropinirole that they should not drive or operate dangerous machinery until they are certain that ropinirole does not cause excessive drowsiness. If sleep attacks occur, the patient must not drive and must inform their prescriber immediately. The risk of somnolence is greater at higher doses and when ropinirole is combined with central depressants (alcohol, sedatives, opioids).

How is ropinirole safely stopped?

Ropinirole must never be stopped abruptly — particularly in patients with established Parkinson's disease. Abrupt withdrawal of dopamine agonists (or dopaminergic therapy broadly) in PD can precipitate dopamine agonist withdrawal syndrome (DAWS) — characterised by craving, anxiety, panic attacks, depression, and autonomic features — or in severe cases a neuroleptic malignant syndrome (NMS)-like reaction with hyperthermia, severe rigidity, autonomic instability, and confusion. Doses should be tapered gradually over a period of weeks under direct medical supervision. If switching from ropinirole IR to ropinirole ER (Requip XL), conversion is done on a per-dose equivalence basis. Any change to dopaminergic therapy in a Parkinson's patient should be managed by their specialist team.

← Back to Parkinson's Disease Medications